KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Interest Expenses (2019 - 2025)

Historic Interest Expenses for Rigel Pharmaceuticals (RIGL) over the last 10 years, with Q3 2025 value amounting to $1.9 million.

  • Rigel Pharmaceuticals' Interest Expenses fell 805.83% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 373.57%. This contributed to the annual value of $7.9 million for FY2024, which is 1522.12% up from last year.
  • Rigel Pharmaceuticals' Interest Expenses amounted to $1.9 million in Q3 2025, which was down 805.83% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Interest Expenses ranged from a high of $2.1 million in Q3 2024 and a low of $485000.0 during Q1 2021
  • Its 5-year average for Interest Expenses is $1.5 million, with a median of $1.9 million in 2025.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Interest Expenses soared by 39830.03% in 2021 and then crashed by 6765.21% in 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' Interest Expenses (Quarter) stood at $1.3 million in 2021, then fell by 14.78% to $1.1 million in 2022, then surged by 72.27% to $1.9 million in 2023, then rose by 2.52% to $2.0 million in 2024, then decreased by 3.12% to $1.9 million in 2025.
  • Its Interest Expenses was $1.9 million in Q3 2025, compared to $1.9 million in Q2 2025 and $1.9 million in Q1 2025.